Cyanotech Corporation (CYAN)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	24.22	23.07	23.18	35.97	32.35
Revenue Growth (YoY)	4.96%	-0.46%	-35.56%	11.20%	1.40%
Cost of Revenue	17.23	16.92	15.83	22.4	21.12
Gross Profit	6.99	6.15	7.35	13.57	11.23
Selling, General & Admin	8.94	9.85	9.41	10.28	10.39
Research & Development	0.45	0.69	0.77	0.71	0.64
Operating Expenses	9.38	10.54	10.18	10.99	11.03
Operating Income	-2.4	-4.39	-2.83	2.57	0.19
Interest Expense	-0.69	-0.67	-0.5	-0.39	-0.55
EBT Excluding Unusual Items	-3.08	-5.05	-3.33	2.18	-0.36
Other Unusual Items	-0.11	-0.21	-0.09	-	1.28
Pretax Income	-3.2	-5.26	-3.42	2.18	0.92
Income Tax Expense	0.01	0.01	0.02	0.03	0
Net Income	-3.2	-5.27	-3.44	2.15	0.92
Net Income to Common	-3.2	-5.27	-3.44	2.15	0.92
Net Income Growth	-	-	-	134.13%	137.73%
Shares Outstanding (Basic)	7	7	6	6	6
Shares Outstanding (Diluted)	7	7	6	6	6
Shares Change (YoY)	8.27%	4.60%	1.23%	1.46%	2.01%
EPS (Basic)	-0.45	-0.81	-0.55	0.35	0.15
EPS (Diluted)	-0.45	-0.81	-0.55	0.35	0.15
EPS Growth	-	-	-	133.23%	150.00%
Free Cash Flow	-1.44	-0.84	-3.17	1.11	1.64
Free Cash Flow Per Share	-0.20	-0.13	-0.51	0.18	0.27
Gross Margin	28.86%	26.66%	31.71%	37.72%	34.71%
Operating Margin	-9.89%	-19.01%	-12.21%	7.16%	0.60%
Profit Margin	-13.23%	-22.83%	-14.84%	5.99%	2.84%
Free Cash Flow Margin	-5.95%	-3.62%	-13.67%	3.08%	5.07%
EBITDA	-0.89	-2.81	-1.14	4.23	2.03
EBITDA Margin	-3.68%	-12.18%	-4.90%	11.76%	6.28%
D&A For EBITDA	1.5	1.58	1.7	1.66	1.84
EBIT	-2.4	-4.39	-2.83	2.57	0.19
EBIT Margin	-9.89%	-19.01%	-12.21%	7.16%	0.60%
Effective Tax Rate	-	-	-	1.28%	0.33%
Advertising Expenses	1.12	1.31	1.51	1.46	2.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.